ANALYSIS
Methodology note: Historical index values on this Pulse are normalized to the current methodology for comparability. The original as-published record remains unchanged in the canonical archive.
Verdict
The last 24 hours contain one genuinely material broader-acceleration event but no new ASI capability jump. Intismeran, Moderna/Merck's individualized mRNA neoantigen therapy, met the primary recurrence-free-survival endpoint and a metastasis-related secondary endpoint in Phase 3 melanoma. This is strong clinical validation for programmable, patient-specific biological design. Because detailed numerical results and overall-survival data remain pending, the move is deliberately modest and confined to SynBio clinical/industrial validation.
Frontier intelligence / reasoning / agents / coding-AI R&D
Double-pass release coverage across OpenAI, Anthropic, Google DeepMind, SpaceXAI/xAI, DeepSeek and Qwen/Alibaba found no verified new flagship/frontier release in the 24h window. OpenAI's public product surface remains on GPT-5.6; Gemini API release notes remain on Gemini 3.7 Flash from Aug 13; DeepSeek V4 Pro and Qwen3.8-Max are already tracked; xAI first-party news surfaces show no newer verified flagship release. Rumors about upcoming Anthropic/OpenAI models remain rumors and are excluded.
AI for Science
No new verified AI-assisted scientific result in the 24h window crosses the maturity threshold. AI for Science remains 56.4/100.
Open Problem Closure Radar
Targeted arXiv searches across mathematics, theoretical CS, quantum and physics, plus VibeMathed review, found no new named-problem record meeting the registration threshold after the previous Daily. New records=0; status changes=0; new AI-material records=0. The radar audit remains partial because exhaustive enumeration of every arXiv daily submission cannot be guaranteed through the available index.
Robotics
No new evidence on unattended useful hours, intervention rate, broad task generalization or deployment reliability changes Robotics maturity. World Robot Conference reporting reinforces industrial-scale momentum in China, but much current humanoid volume remains non-commercial/research-oriented and athletic demos are not general-purpose autonomy. Robotics remains 47.4/100.
Compute & Infrastructure
No new compute event in the current window changes the frontier. Alibaba's M890 supernode availability is not fresh: the underlying architecture was announced earlier and public-cloud service had already entered service before this window. Compute remains 75.1/100.
Synthetic Biology / gene engineering
Material event: Intismeran (V940) + pembrolizumab met Phase 3 melanoma endpoints. Independent reporting describes statistically and clinically significant improvements in recurrence-free survival and prevention of distant metastasis versus pembrolizumab alone, with no new safety signal reported. The trial registry confirms a randomized Phase 3 study in high-risk resected stage II-IV melanoma. Detailed numerical results and overall survival remain pending.
Evidence 88/100; relevance 8.2/10; ASI impact 1.0/10 indirect; SynBio-frontier impact high. Clinical & industrial validation moves 66→69; other SynBio components remain unchanged. Weighted SynBio maturity moves 66.0→66.8. This does not enter ASI Readiness under the versioned formula.
Energy / Fusion
No new integrated net-electricity, plant-lifetime, licensing/construction or $/MWh milestone in the window. Energy/Fusion remains 46.8/100.
Advanced Materials
No new experimentally validated autonomous-discovery result or manufacturing-scale transition crosses the maturity threshold. Materials remains 62.4/100.
Longevity
No new Phase 2/3 rejuvenation endpoint or convincing human-age-reversal signal was found. Longevity remains 36.3/100.
BCI/HMI
No new durable bandwidth, bidirectionality, stability, patient-scale or real-world-use milestone was found. BCI remains 42.8/100.
Benchmark Observatory
METR Time Horizon remains on TH1.1 with its public frontier page last updated May 8, 2026. No new official Humanity's Last Exam or FrontierMath point requiring ingestion was found.
Readiness and forecast
Intelligence 63.7/100 (Δ0.0); AI for Science 56.4/100 (Δ0.0); Robotics 47.4/100 (Δ0.0). ASI Readiness 58.2/100 (Δ0.0). SynBio 66.8/100 (Δ+0.8; overlay only). Singularity Readiness remains 52.61/100.
Rolling ASI probabilities remain 1y 2%, 2y 6%, 3y 12%, 5y 30%, 10y 81%, all Δ0 percentage points.
Primary ASI bottlenecks remain long-horizon autonomous reliability, automated AI-R&D loop closure, scientific verification at scale and robotic reliability/generalization. Broader technological bottlenecks remain physical compute scaling, programmable-biology delivery/control, fusion plant integration, materials validation-to-manufacturing, human rejuvenation evidence and stable high-bandwidth BCI.
24–48h missed-event audit
No verified relevance>=7 event that had existed for at least two hours was found missing from the database at audit time. Intismeran had already been captured by the live watch before Daily publication. No missing qualifying Open Problem record was found. missed_event_count=0. audit_status=partial only because exhaustive arXiv daily-feed enumeration cannot be guaranteed through the available search index.